Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06989359 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
A Phase 2 study of IgAN and C3G, sponsored by ADARx Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 12
- Study locations
NCT06989359: Recruiting Phase 2 study of IgAN and C3G, sponsored by ADARx Pharmaceuticals.
NCT06989359 is a Phase 2 study of IgAN and C3G that is actively recruiting participants, run by ADARx Pharmaceuticals. The registered enrollment target is 45 participants, below the 245-participant average among 3 other IgAN trials with a reported enrollment target (82% lower). The trial reports 12 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06989359, a Phase 2 study of IgAN and C3G, is actively recruiting participants, sponsored by ADARx Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 12
- Study locations
Study Summary
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Primary Outcome
Incidence and severity of TEAEs
Conditions Studied
Interventions
- DRUG ADX-038 Dose Level 2
- DRUG ADX-038 Dose Level 1
Study Locations (12)
Other
- ADARx Clinical Site - Pok Fu Lam
- ADARx Clinical Site - Shatin
- ADARx Clinical Site - Cheonan
- ADARx Clinical Site - Seoul
New South Wales
- ADARx Clinical Site - Wollongong
- ADARx Clinical Site - Gyeonggi-do
- ADARx Clinical Site - Seoul
Texas
- ADARx Clinical Site - Dallas
- ADARx Clinical Site - Houston
Louisiana
- ADARx Clinical Site - Shreveport
Michigan
- ADARx Clinical Site - Shelby
South Dakota
- ADARx Clinical Site - Dakota Dunes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2028-07 |
| Phase | Phase 2 |
What NCT06989359 shows while recruiting
NCT06989359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 245-participant average among 3 other IgAN trials with a reported enrollment target (82% lower).
The record links to 5 conditions, with IgAN appearing as the primary indexed condition, and to 2 interventions - of which ADX-038 Dose Level 2 is the first listed.
NCT06989359 lists 12 locations in 6 states (Other, New South Wales, Texas).
Frequently Asked Questions
What is clinical trial NCT06989359 about?
NCT06989359 is a clinical study titled "Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease". This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
What is the current status of trial NCT06989359?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-08-28. Estimated completion is 2028-07.
What conditions does trial NCT06989359 study?
This clinical trial studies the following conditions: IgAN, C3G, IC-MPGN, IgA Nephropathy (IgAN), Complement-mediated Kidney Disease.
What interventions are being tested in trial NCT06989359?
The interventions under investigation include: ADX-038 Dose Level 2 (DRUG), ADX-038 Dose Level 1 (DRUG).
Who is sponsoring clinical trial NCT06989359?
This trial is sponsored by ADARx Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06989359 being conducted?
This trial has 12 study locations across Louisiana, Michigan, South Dakota, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgAN
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI